NYSE:LLYPharmaceuticals
Evaluating Eli Lilly’s Valuation After Recent Share Price Pullback And Tirzepatide Growth Expectations
Eli Lilly (LLY) has been drawing fresh attention after recent share price moves, with the stock down about 7% over the past month but up roughly 8% in the past 3 months.
See our latest analysis for Eli Lilly.
Despite the recent 1 month share price return of about a 7% decline and a 7% year to date share price decline, Eli Lilly still has a 1 year total shareholder return of 22.38% and a very large 5 year total shareholder return of 424.22%. This suggests long term momentum has been strong...